Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 53Carcinoma, Renal Cell 37Lung Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 21Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Colorectal Neoplasms 17Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 13Prostatic Neoplasms 11Hodgkin Disease 11Brain Neoplasms 10Urinary Bladder Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Sarcoma 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

olaparib 1lutetium Lu 177 dotatate 1lanreotide 1fluorodopa F 18 1cabozantinib 1Sunitinib 1Random Allocation 1Octreotide 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Nivolumab × 90 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡